IAC Express 2009 |
Issue number 813: July 27, 2009 |
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
Contents
of this Issue
Select a title to jump to the article. |
- CDC's
2009 recommendations for prevention and control of seasonal influenza
published as an MMWR Early Release
- ACIP
votes on recommendations for many vaccines at its June 24-26 meeting
- MMWR
publishes report on neurological complications associated with H1N1
influenza in children in May 2009
- Four
states expand immunization requirements; pharmacists authorized to
vaccinate in all 50 states
- FDA
approves seasonal influenza vaccines for 2009-10; package inserts for all
vaccines are on IAC's website
- CDC
summarizes H1N1 influenza situation and advises the healthcare community
and public on ways to stay informed
- IAC's
Video of the Week presents HHS Secretary Sebelius explaining the 2009 Flu
Prevention PSA contest
- IAC's
padded screening questionnaires for contraindications have English on
front, Spanish on back--added value at no added cost!
- July
issue of CDC's Immunization Works electronic newsletter recently released
- Clinical
trials to test two candidate H1N1 influenza vaccines to begin soon
- CDC's
H1N1 influenza web section updated with Q&As on H1N1 influenza vaccine
development and more
- Engaging
booklet helps the public evaluate science articles that appear in the
media
- It's
easy to give patients basic immunization information with CDC's
attractive, formatted articles
- FREE
online CE course on best practices in childhood and adolescent
immunization now available
|
|
Abbreviations |
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
|
Issue 813: July 27, 2009 |
|
|
1. |
CDC's 2009 recommendations for
prevention and control of seasonal influenza published as an MMWR Early
Release
On July 24, CDC published "Prevention and Control
of Seasonal Influenza with Vaccines: Recommendations of the Advisory
Committee on Immunization Practices (ACIP), 2009" as an electronic MMWR Early
Release. The Summary is reprinted below. At the end of this IAC Express
article, URLs will be given to two items that will be of particular interest
to some readers: "BOX 1. Summary of seasonal influenza vaccination
recommendations, 2009: children and adolescents aged 6 months-18 years" and
"BOX 2. Summary of seasonal influenza vaccination recommendations, 2009:
adults."
Summary
This report updates the 2008 recommendations by CDC's
Advisory Committee on Immunization Practices (ACIP)
regarding the use of influenza vaccine for the prevention
and control of seasonal influenza. Information on
vaccination issues related to the recently identified novel
influenza A H1N1 virus will be published later in 2009. The
2009 seasonal influenza recommendations include new and
updated information. Highlights of the 2009 recommendations
include (1) a recommendation that annual vaccination be
administered to all children aged 6 months-18 years for the
2009-10 influenza season; (2) a recommendation that
vaccines containing the 2009-10 trivalent vaccine virus
strains A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007
(H3N2)-like, and B/Brisbane/60/2008-like antigens be used;
and (3) a notice that recommendations for influenza
diagnosis and antiviral use will be published before the
start of the 2009-10 influenza season. Vaccination efforts
should begin as soon as vaccine is available and continue
through the influenza season. Approximately 83% of the
United States population is specifically recommended for
annual vaccination against seasonal influenza; however,
<40% of the U.S. population received the 2008-09 influenza
vaccine. These recommendations also include a summary of
safety data for U.S. licensed influenza vaccines. These
recommendations and other information are available at
CDC's influenza website (http://www.cdc.gov/flu); any
updates or supplements that might be required during the
2009-10 influenza season also can be found at this website.
Vaccination and healthcare providers should be alert to
announcements of recommendation updates and should check
the CDC influenza website periodically for additional
information. . . .
To access a ready-to-print (PDF) version of this MMWR Early
Release, go to:
http://www.cdc.gov/mmwr/pdf/rr/rr58e0724.pdf
To access a web-text (HTML) version of this MMWR Early
Release, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0724a1.htm
To receive a FREE electronic subscription to MMWR (which
includes new ACIP recommendations), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
To access "BOX 1. Summary of seasonal influenza vaccination
recommendations, 2009: children and adolescents aged 6
months-18 years," go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0724a1.htm#box1
To access "BOX 2. Summary of seasonal influenza vaccination
recommendations, 2009: adults," go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0724a1.htm#box2
Back to top |
|
|
2. |
ACIP votes on recommendations for
many vaccines at its June 24-26 meeting
[The following is cross posted from the "Front
Page News"
section of CDC's Immunization Works electronic newsletter,
July 2009.]
ACIP HIGHLIGHTS: The Advisory Committee on Immunization
Practices (ACIP) met June 24–26 in Atlanta, adding an extra
half-day to their usual schedule to address the issue of
influenza vaccination now that novel influenza A H1N1 is
considered a pandemic influenza virus strain. The meeting
produced several new and updated recommendations. These
recommendations are provisional until they are reviewed by
the director of CDC and published in the MMWR. Full minutes
of the meeting, including slides from presentations, will
be available soon on the ACIP Meetings web page
(http://www.cdc.gov/vaccines/recs/acip/meetings.htm ).
General Recommendations: A clarification was made to the
General Recommendations regarding combination vaccines,
maintaining a general preference for combination vaccine
products, but stating specific criteria by which a provider
might choose the single-component products. Important
considerations include provider assessment, patient
preference, and potential for adverse events.
Rabies Vaccine: The committee voted to reduce the number of
rabies prevention from five to four. The schedule for
administration of the doses is days 0, 3, 7, and 14. For
more information, please see the Rabies Provisional
Recommendation
(http://www.cdc.gov/vaccines/recs/provisional/downloads/rabies-July2009-508.pdf).
Polio Vaccine: The minimum interval between dose 3 and dose
4 of polio-containing vaccines was changed from 4 weeks to
6 months.
Measles-Mumps-Rubella Vaccine: Modifications were made to
the criteria for acceptable evidence of immunity to
measles, mumps, and rubella for healthcare providers.
Documentation of physician-diagnosed disease (previously
considered evidence of measles and mumps immunity) is no
longer an acceptable criterion. Birth before 1957 is still
evidence of immunity, but facilities should consider
vaccinating healthcare providers born before 1957 who have
no other criterion for immunity with two doses of MMR
vaccine. In an outbreak, two doses of vaccine are
specifically recommended for healthcare providers born
before 1957.
Meningococcal Vaccine: A recommendation was made for
revaccination using meningococcal conjugate vaccine for
persons who remain at high risk for meningococcal disease
after their first vaccination (with either the
polysaccharide or the conjugate meningococcal vaccine).
These include persons with persistent complement component
deficiencies, persons with anatomic or functional asplenia,
persons infected with HIV, microbiologists who are
routinely exposed to Neisseria meningitidis, and frequent
travelers to or people living in areas with high rates of
meningococcal disease, such as the African meningitis belt.
For children 2 through 6 years of age the dose should be
given at an interval of 3 years, for persons older than 6
years, at an interval of 5 years.
Japanese Encephalitis Vaccine: The ACIP voted to include
the recently licensed Japanese encephalitis virus (JEV)
vaccine, Ixiaro, in the list of recommended vaccines for
U.S. travelers. Clarifications were also made to the
existing recommendations for the use of Japanese
encephalitis vaccine. The vaccine is recommended for
travelers who will spend 1 month or more in an endemic-disease area during the JEV transmission season, or for
short-term travelers if they have an increased risk of JEV
exposure. The vaccine is not recommended for short-term
travelers whose visit will be restricted to urban areas or
times outside of a well-defined JEV transmission season.
For more information, please see the Japanese Encephalitis
Provisional Recommendation
(http://www.cdc.gov/vaccines/recs/provisional/downloads/je-july2009-508.pdf).
Measles-Mumps-Rubella-Varicella Vaccine: Additional
language was added to the recommendation for MMRV vaccine
regarding combination vaccines versus separate injections
of equivalent component vaccines. Combination vaccines are
preferred, but considerations should include provider
assessment, patient preference, and the potential for
adverse events. In addition, a personal or family history of seizures was
included as a precaution for MMRV vaccine use.
[The following is cross posted from the "More News &
Summaries" section of CDC's Immunization Works electronic
newsletter, July 2009.]
HIB BOOSTER DOSE REINSTATED: CDC, in consultation with
ACIP, the American Academy of Family Physicians, and the
American Academy of Pediatrics, is recommending
reinstatement of the booster dose of Haemophilus influenzae
type b vaccine for children aged 12–15 months who have
completed the primary 3-dose series. Infants should
continue to receive the primary Hib vaccine series at ages
2, 4, and 6 months. Children aged 12–15 months should
receive the booster dose on time. Older children for whom
the booster dose was deferred should receive their Hib
booster dose at the next routinely scheduled visit or
medical encounter. Although supply is sufficient to
reinstate the booster dose and begin catch-up vaccination,
supply is not yet ample enough to support a mass
notification process to contact all children with deferred
Hib booster doses. For more information, please see the
Updated Recommendations for Use of Hib full article in
CDC's Morbidity and Mortality Weekly Report
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5824a5.htm).
Also, CDC has posted Hib Vaccine: Q&A for Providers about
the Return to the Hib "Booster" Dose
(http://www.cdc.gov/vaccines/vpd-vac/hib/faqs-return-to-booster-hcp.htm).
Back to top |
|
|
3. |
MMWR publishes report on
neurological complications associated with H1N1 influenza in children in May
2009
CDC published "Neurologic Complications
Associated with
Novel Influenza A (H1N1) Virus Infections in Children--Dallas, Texas, May 2009" in the July 24 issue of MMWR. The
opening paragraph of the article is reprinted below.
Neurologic complications, including seizures, encephalitis,
encephalopathy, Reye syndrome, and other neurologic
disorders, have been described previously in association
with respiratory tract infection with seasonal influenza A
or B viruses, but not with novel influenza A (H1N1) virus.
On May 28, 2009, the Dallas County Department of Health and
Human Services (DCHHS) notified CDC of four children with
neurologic complications associated with novel influenza A
(H1N1) virus infection admitted to hospitals in Dallas
County, Texas, during May 18-28. This report summarizes the
clinical characteristics of those four cases. Patients were
aged 7-17 years and were admitted with signs of influenza-like illness (ILI) and seizures or altered mental status.
Three of the four patients had abnormal
electroencephalograms (EEGs). In all four patients, novel
influenza A (H1N1) viral RNA was detected in nasopharyngeal
specimens but not in cerebrospinal fluid (CSF). Antiviral
therapy included oseltamivir (four patients) and
rimantadine (three patients). All four patients recovered
fully and had no neurologic sequelae at discharge. These
findings indicate that, as with seasonal influenza,
neurologic complications can occur after respiratory tract
infection with novel influenza A (H1N1) virus. For children
who have ILI accompanied by unexplained seizures or mental
status changes, clinicians should consider acute seasonal
influenza or novel influenza A (H1N1) virus infection in
the differential diagnosis, send respiratory specimens for
appropriate diagnostic testing, and promptly initiate
empirical antiviral treatment, especially in hospitalized
patients. . . .
To access a web-text (HTML) version of the complete
article, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5828a2.htm
To access a ready-to-print (PDF) version of this issue of
MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5828.pdf
Back to top |
|
|
4. |
Four states expand immunization
requirements; pharmacists authorized to vaccinate in all 50 states
Florida, Georgia, Nebraska, and Texas have
recently
expanded their immunization requirements for pre-school or
school attendance. In June, Maine became the 50th state to
authorize pharmacists to vaccinate. More detailed
information follows. [Note: "School year" is abbreviated as
SY throughout this IAC Express article.]
INFLUENZA INFORMATION
Florida: On June 10, the governor approved a bill making it
a legal requirement that each year, in August or September,
certain child care and day care providers distribute
detailed information about influenza (i.e., causes,
symptoms, and transmission) to the parents of enrolled
children. The goal is to educate parents about the
importance of annual influenza vaccination of their
children. The law went into effect on June 10 and will be
implemented in August and September 2009.
Note: At this time, IAC has no chart that lists influenza
laws for child care or day care attendance.
MENINGOCOCCAL INFORMATION/VACCINATION
Georgia: On May 5, the governor signed a law requiring
schools to provide parents/guardians of students in grades
6 through 12 with information on meningococcal meningitis
disease/vaccine. The requirement will be effective for SY
2009-10.
Texas: On March 5, the executive commissioner of Health and
Human Services (HHS) approved a revision to the state's
administrative code that requires 1 dose of meningococcal
conjugate vaccine (MCV) for students entering grade 7. The
requirement goes into effect on August 1; it will phase
into higher grades, leading up to grade 12 by SY 2014-15.
IAC has compiled a chart of information about all states
that have meningococcal prevention mandates for elementary
and secondary school attendance. To access the information,
go to:
http://www.immunize.org/laws/menin_sec.asp
This information is also depicted visually on a map of the
United States. To access the map, go to:
http://www.immunize.org/laws/menin_sec.pdf
TETANUS-DIPHTHERIA-ACELLULAR PERTUSSIS (Tdap) VACCINATION
Nebraska: On May 27, the governor approved a requirement
for a one-time dose of Tdap vaccine for all students
entering grade 7. The requirement becomes effective on July
1, 2010.
Texas: On March 5, the executive commissioner of HHS
approved a revision to the state's administrative code that
requires a one-time dose of Tdap for all students entering
grade 7. The requirement goes into effect on August 1; it
will phase into higher grades, leading up to grade 12 by SY
2014-15.
IAC has compiled a chart of information about all states
that require Tdap vaccination for middle school and high
school attendance. To access the information, go to:
http://www.immunize.org/laws/tdap_mandates.pdf
This information is also depicted visually on a map of the
United States. To access the map, go to:
http://www.immunize.org/laws/tdap.pdf
HEPATITIS A VACCINATION
Texas: On March 5, the executive commissioner of HHS
approved a revision to the state's administrative code that
requires evidence of 2 doses of hepatitis A vaccine for
students entering kindergarten. The requirement goes into
effect on August 1; it will phase into higher grades,
leading up to grade 12 by SY 2021-22.
IAC has compiled a chart of information about all states
that have hepatitis A prevention mandates for day care and
school attendance. To access the information, go to:
http://www.immunize.org/laws/hepa.asp
MEASLES-MUMPS-RUBELLA (MMR) VACCINATION
Texas: On March 5, the executive commissioner of HHS
approved a revision to the state's administrative code that
requires evidence of 2 doses of MMR vaccine for students
entering kindergarten. The requirement goes into effect on
August 1; it will phase into higher grades, leading up to
grade 12 by SY 2021-22.
CDC has compiled a chart of information about all states
that require 2 doses of measles-containing vaccine for kindergarten entry. To
access the information, go to:
http://www.immunize.org/laws/mmr_kinder_2nddose.pdf Note:
the information is current for SY 2007-08; CDC has not yet
updated it for SY 2009-10.
VARICELLA VACCINATION
Texas: On March 5, the executive commissioner of HHS
approved a revision to the state's administrative code that
requires evidence of 2 doses of varicella vaccine for
students entering either kindergarten or grade 7 (disease
history of chickenpox may be substituted for varicella
vaccine). The requirement goes into effect on August 1; it
will phase into higher grades, leading up to grade 12 by SY
2014-15.
IAC has compiled a chart of information about all states
that require 2 doses of varicella vaccine for child care
and school attendance. To access the information, go to:
http://www.immunize.org/laws/var2_mandates.pdf
This information is also depicted visually on a map of the
United States. To access the map, go to:
http://www.immunize.org/laws/vari_two.pdf
PHARMACIST AUTHORIZATION TO VACCINATE
Maine: On June 9, the governor signed legislation that will
allow licensed pharmacists to administer certain drugs and
vaccines.
IAC has compiled a chart of information about all states
that authorize pharmacists to administer vaccinations. To
access the information, go to:
http://www.immunize.org/laws/#pharm
This information is also depicted visually on a map of the
United States. To access the map, go to:
http://www.immunize.org/pdfs/pharm.pdf
WANT MORE INFORMATION ON STATE IMMUNIZATION MANDATES?
To access more information about state mandates, visit our
State Mandates on Immunization and Vaccine-Preventable Diseases web section
at http://www.immunize.org/laws
IAC Express depends on readers to help us stay informed and
ensure our website contains the most current and accurate
information available. Please let us know when any changes
occur in your state by emailing us at admin@immunize.org
The CDC website has a section of resources on immunization
requirements for school attendance, healthcare workers,
patients in various healthcare settings, and residents of
various institutional settings. Among the resources is a
searchable database on state immunization laws. To access
this section of resources, go to:
http://www.cdc.gov/vaccines/vac-gen/laws/default.htm
Back to top |
|
|
5. |
FDA approves seasonal influenza
vaccines for 2009-10; package inserts for all vaccines are on IAC's website
On July 20, FDA issued a press release announcing
that it
has approved the vaccine for 2009-10 seasonal influenza. A
portion of it is reprinted below.
Editor's note: The press release includes the brand names
of the six vaccines approved for use during the 2009-10
seasonal influenza season. At the end of this IAC Express
article, readers will find links to IAC's package inserts
web page for the 2009-10 live attenuated influenza vaccine
(LAIV) and 2009-10 trivalent inactivated influenza vaccines
(TIV; injectable).
The U.S. Food and Drug Administration today announced that
it has approved a vaccine for 2009-2010 seasonal influenza
in the United States.
The seasonal influenza vaccine will not protect against
the 2009 H1N1 influenza virus that resulted in the
declaration of a pandemic by the World Health Organization
(WHO) on June 11, 2009. The FDA continues to work with
manufacturers, international partners, and other
government agencies to facilitate the availability of a
safe and effective vaccine against the 2009 H1N1 influenza
virus. . . .
The vaccine for the 2009-2010 seasonal influenza contains:
- an A/Brisbane/59/2007 (H1N1)-like virus
- an A/Brisbane/10/2007 (H3N2)-like virus
- a B/Brisbane/60/2008-like virus . . . .
To access the complete press release, go to:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172772.htm
PACKAGE INSERTS NOW AVAILABLE
To access IAC's web page of package inserts for FluMist
(LAIV), go to:
http://www.immunize.org/packageinserts/pi_laiv.asp
To access IAC's web page of package inserts for TIV, go to:
http://www.immunize.org/packageinserts/pi_tiv.asp
To access IAC's index page of package inserts for 25
vaccine, go to:
http://www.immunize.org/packageinserts
Back to top |
|
|
6. |
CDC summarizes H1N1 influenza
situation and advises the healthcare community and public on ways to stay
informed
[The following is cross posted from the "More
News &
Summaries" section of CDC's Immunization Works electronic
newsletter, July 2009.]
NOVEL H1N1 INFLUENZA UPDATE: CDC estimates that there have
been at least one million cases of novel H1N1 influenza in
the United States. CDC's goals during this public health
emergency are to reduce transmission and illness severity,
and to provide information to assist healthcare providers,
public health officials, and the public in addressing the
challenges posed by this newly identified influenza virus.
Vaccines are a very important part of a response to
pandemic influenza. CDC has isolated the novel H1N1 virus,
made a candidate vaccine virus strain that can be used to
create vaccine, and has provided this virus to industry so
they can begin scaling up for production of a vaccine. It
is expected that novel H1N1 influenza vaccine may be
available as early as mid-October. On July 8, 2009, CDC
issued guidance for state and local public health
departments to assist them in planning for a novel H1N1
influenza vaccine campaign
(http://www.cdc.gov/h1n1flu/vaccination/statelocal/planning.htm).
For the latest information about the novel Influenza A
(H1N1) outbreak and CDC's response, visit CDC's H1N1
influenza website (http://www.cdc.gov/h1n1flu), sign up to
receive CDC email updates (https://service.govdelivery.com/service/subscribe.html?code=USCDC_53),
subscribe to RSS (http://www.cdc.gov/h1n1flu/rss), or follow
CDC Emergency on Twitter (http://twitter.com/cdcemergency).
Back to top |
|
|
7. |
IAC's Video of the Week presents
HHS Secretary Sebelius explaining the 2009 Flu Prevention PSA contest
IAC encourages IAC Express readers to watch a
1-minute
video that encourages people to create a 15-, 30-, or 60-second public service announcement (PSA) that will inform
and motivate people to take steps that will help prevent
the spread of influenza. In the video, Department of Health
and Human Services (HHS) Secretary Kathleen Sebelius
presents details about the contest rules.
The video will be available on the home page of IAC's website through August
2. To access it, go to: http://www.immunize.org and click on the image under the
words Video of the Week. It may take a few moments for the
video to begin playing; please be patient!
Remember to bookmark IAC's home page to view a new video
every Monday. To view an IAC Video of the Week from the
past, go to the video archive at
http://www.immunize.org/votw/jun09.asp
Back to top |
|
|
8. |
IAC's padded screening
questionnaires for contraindications have English on front, Spanish on
back--added value at no added cost!
In response to demand, IAC now has a
Spanish-language
translation of the questions on its padded Screening
Questionnaire for Child and Teen Immunization and Screening
Questionnaire for Adult Immunization. Printed on the back
of the English page, the Spanish page has been added to
this product at no additional cost.
The questionnaires give you and your patients a quick,
easy, and thorough way to determine if they have contraindications and
precautions to vaccination. Patients fill out the questionnaire with
yes-or-no answers while waiting to be seen, allowing you to review their
responses
quickly and be confident you're not missing any
contraindications or precautions.
The questionnaires come in convenient tear-off pads of 100
sheets. The price per pad is economical (discounts for two
pads or more), so you'll be able to keep pads at the
receptionist's desk, the nurse's station, and in every exam
room. Each pad comes with four English-language reference
sheets (printed on heavy-weight paper) for health
professionals.
Prices start at $16 each for one pad and drop to $12 each
for two, $11 each for three, and $10 each for four. For
quotes on larger quantities or customizing, call (651) 647-9009 or email admininfo@immunize.org
To learn more about the padded screening questionnaires, or
to order online or download an order form, visit
Screening Questionnaire for Child and Teen Immunization
http://www.immunize.org/shop/pad_sqchild.asp
Screening Questionnaire for Adult Immunization
http://www.immunize.org/shop/pad_sqadult.asp
IAC's offers other products for sale, including educational
videos and personal immunization record cards, at
http://www.immunize.org/shop
Back to top |
|
|
9. |
July issue of CDC's Immunization
Works electronic newsletter recently released
CDC recently released the July issue of its
monthly
newsletter Immunization Works and posted it on the website
of the National Center for Immunization and Respiratory
Diseases (NCIRD). The newsletter offers the immunization
community information about current topics. The information
is in the public domain and can be reproduced and
circulated widely.
Some of the information in the July issue has already
appeared in previous issues of IAC Express. Following is
the text of some articles we have not covered.
MEETINGS, CONFERENCES &RESOURCES
IMMUNIZATION UPDATE 2009: Please mark your calendars for
the July 30, 2009, Live Satellite Broadcast and Webcast
from CDC's National Center for Immunization and Respiratory
Diseases. This 2.5-hour program focuses on the most recent
developments in the rapidly changing field of immunization,
including new vaccine recommendations. The event will take
place from 9:00 AM-11:30 AM and noon-2:30 PM Eastern time.
For more information, visit CDC's Immunization Education
and Training Webcasts web page
(http://www.cdc.gov/vaccines/ed/webcasts.htm).
RESPIRATORY NEWS AND RESOURCES
MENINGITIS WEBSITE: A new CDC Meningitis website
(http://www.cdc.gov/meningitis) was launched June 24. The
site contains comprehensive information on bacterial,
viral, and other types of meningitis, as well as on
meningococcal vaccines. Links on the site lead to a variety
of additional educational and vaccine-related resources.
WORLD PNEUMONIA DAY: Mark your calendars for "World
Pneumonia Day", November 2, 2009. This event--led by child
health groups and Save the Children Artist Ambassadors
Gwyneth Paltrow and Hugh Laurie--will bring needed
attention to a neglected disease that kills more than two
million children under the age of five each year,
worldwide. For more information or to sign up to receive
email updates, visit the World Pneumonia Day website
(http://www.worldpneumoniaday.org).
To access the complete July issue from the NCIRD website,
go to:
http://www.cdc.gov/vaccines/news/newsltrs/imwrks/2009/200907.htm
Back to top |
|
|
10. |
Clinical trials to test two
candidate H1N1 influenza vaccines to begin soon
On July 22, the National Institutes of Health
(NIH) issued
a press release, "NIAID Set to Launch Clinical Trials to
Test 2009 H1N1 Influenza Vaccine Candidates." Portions of
the press release are reprinted below.
Scientists in a network of medical research institutions
across the United States are set to begin a series of
clinical trials to gather critical data about influenza
vaccines, including two candidate H1N1 flu vaccines. The
research will be under the direction of the National
Institute of Allergy and Infectious Diseases (NIAID), part
of the National Institutes of Health.
"With the emergence of the 2009 H1N1 influenza virus, we
have undertaken a collaborative and efficient process of
vaccine development that is proceeding in stepwise
fashion," says NIAID Director Anthony S. Fauci, MD.
After the isolation and characterization of the virus, the
U.S. Centers for Disease Control and Prevention generated
and distributed a 2009 H1N1 seed virus to vaccine
manufacturers for the development of vaccine pilot lots for
testing in clinical trials.
"Now, NIAID will use our longstanding vaccine clinical
trials infrastructure--the Vaccine and Treatment Evaluation
Units--to help quickly evaluate these pilot lots to
determine whether the vaccines are safe and to assess their
ability to induce protective immune responses," says Dr.
Fauci. "These data will be factored into the decision about
how and if to implement a 2009 H1N1 flu immunization
program this fall." . . . .
To access the complete press release, go to:
http://www.nih.gov/news/health/jul2009/niaid-22.htm
Back to top |
|
|
11. |
CDC's H1N1 influenza web section
updated with Q&As on H1N1 influenza vaccine development and more
CDC recently posted new or updated information to
various
sub-sections of its H1N1 Flu web section. Following are the
titles and URLs of documents that have been posted since
the July 20 issue of IAC Express:
CDC Novel H1N1 Vaccination Planning Q&A [provides answers,
to the extent they are now known, on H1N1 influenza vaccine
purchase, distribution, allocation, and administration]
http://www.cdc.gov/h1n1flu/vaccination/statelocal/qa.htm
Questions & Answers: Novel H1N1 Influenza Vaccine
http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm
H1N1 Monitoring Questions & Answers [Q&As about CDC's novel
H1N1 influenza surveillance]
http://www.cdc.gov/h1n1flu/reportingqa.htm
CDC Interim Guidance for People who have Close Contact with
Pigs in Non-commercial Settings: Preventing the Spread of
Influenza A Viruses, Including the Novel Influenza A (H1N1)
Virus http://www.cdc.gov/h1n1flu/guidelines_pig_workers.htm
FOR MORE INFORMATION
The home page of CDC's H1N1 Flu web section can be accessed
from http://www.cdc.gov/h1n1flu
IAC has gathered information related to H1N1 influenza in a
single web section at http://www.immunize.org/h1n1
Back to top |
|
|
12. |
Engaging booklet helps the public
evaluate science articles that appear in the media
The London-based organization Sense about Science
has a
downloadable 8-page booklet that healthcare professionals
may want to make their patients aware of. Titled "I don't
know what to believe . . . making sense of science
stories," the booklet explains the peer review process in
simple, everyday language. It is intended to help its
readers know what to look for in judging the validity of
scientific information presented in the mainstream media.
To access the booklet, go to:
http://www.senseaboutscience.org.uk/pdf/ShortPeerReviewGuide.pdf
Back to top |
|
|
13. |
It's easy to give patients basic
immunization information with CDC's attractive, formatted articles
If your health department, clinic, or practice
creates a
publication for patients, you may be interested in learning
that CDC's online newsroom provides formatted one-page
articles at no cost. Intended for use in any publication,
the articles present basic information on various health
topics, including immunization.
You can get publication-ready articles by following the
steps outlined in the three paragraphs that appear under
the Get Email Updates subhead on this page:
http://www.cdc.gov/media/subtopic/matte.htm
To review the text and graphic images presented in
immunization-specific articles, go to:
http://www.cdc.gov/media/subtopic/matte/matteDisease.htm
Scroll down and click on the appropriate graphic image.
Back to top |
|
|
14. |
FREE online CE course on best
practices in childhood and adolescent immunization now available
The National Committee for Quality Assurance
(NCQA) is
offering a free online continuing education (CE) program,
Best Practices in Childhood and Adolescent Immunization.
Intended for physicians, registered nurses, pharmacists,
and other treating practitioners, the program is approved
for 1.5 contact hours.
For additional information, go to:
http://www.ncqa.org/tabid/82/Default.aspx and click on the
appropriate graphic image.
Back to top |
|
|
|